0      0

AM23-ST-04-O - AM23-ST-04-O: THOR/AABB: Prehospital Transfusion: The Latest Evidence and Expert Discussion (Enduring)

Expiration Date: Dec 31, 2025

Credits: None available.

Prehospital transfusion is becoming a common event in the USA and around the world. There are many factors to consider when implementing such a program, like which products should be transfused and when? Which emergency vehicles should carry these products? When should prehospital patients be transfused? How can these transfusions be monitored for adverse events both during and after the transfusion? What are the regulations concerning prehospital transfusion, and who will pay for it? This session will present the latest evidence and expert opinion from leaders in trauma resuscitation on these questions and more.

Learning Objectives:

  • Understand the medical and regulatory fundamentals of implementing a prehospital transfusion program
  • Evaluate the evidence for the use of blood products prehospital and selecting the RhD type of these products
  • Appreciate nature of trauma in pediatric patients and how it differs from adults¬†




  • Luiz Amorim, MD:
    No financial relationships to disclose
  • Andre Cap, MD:
  • Melissa Cushing, MD:
    Cerus: Consultant/Advisory Board (Ongoing); CSL: Consultant/Advisory Board (Ongoing); Haemonetics: Consultant/Advisory Board (Ongoing); Octapharma: Consultant/Advisory Board (Ongoing)
  • Nancy Dunbar, MD:
    No financial relationships to disclose
  • John Holcomb, MD:
    Aspen Medical: Consultant/Advisory Board (Ongoing); BARDA: Consultant/Advisory Board (Ongoing); CCJ Medical: Full-time/Part-time Employee or Owner (Ongoing); decisio health: Full-time/Part-time Employee or Owner (Ongoing); Hemostatics: Consultant/Advisory Board (Ongoing); Oxyband: Consultant/Advisory Board (Ongoing); QinFlow: Consultant/Advisory Board (Ongoing); WFIRM: Consultant/Advisory Board (Ongoing); Zibrio: Consultant/Advisory Board (Ongoing)
  • Denese Marks, PhD:
    Vitrafy Life Sciences: Consultant/Advisory Board (Ongoing)
  • Robert Russell, MD, MPH:
    No financial relationships to disclose
  • Molly Sherwood:
    Janssen Pharmaceuticals: Grant/Research Support (Ongoing)
  • Phillip Spinella, MD:
    Cerus: Consultant/Advisory Board (Ongoing); Haima: Consultant/Advisory Board (Ongoing); Hemanext: Consultant/Advisory Board (Ongoing); Kalocyte: Stock Shareholder (self-managed) (Ongoing); Octapharma: Consultant/Advisory Board (Ongoing)
  • Bethany Weathersby, MEd:
    No financial relationships to disclose
  • CJ Winckler, MD:
    No financial relationships to disclose
  • Mark Yazer, MD:
    grifols: Honoraria (Ongoing), Speaker's Bureau (Ongoing); Hemanext: Consultant/Advisory Board (Ongoing); Terumo: Honoraria (Ongoing), Speaker's Bureau (Ongoing)
  • Pampee Young, MD, PhD:
    Cerus Co: Honoraria (Ongoing); Eluciderm: Consultant/Advisory Board (Ongoing), Full-time/Part-time Employee or Owner (Ongoing); Fresenius: Consultant/Advisory Board (Ongoing)

All relevant financial relationships have been mitigated.

By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available

AM23-ST-04-O: THOR/AABB: Prehospital Transfusion: The Latest Evidence and Expert Discussion (Enduring) Evaluation